about
Structure of the C-Terminal Helical Repeat Domain of Eukaryotic Elongation Factor 2 KinaseThe molecular mechanism of eukaryotic elongation factor 2 kinase activationModeling organochlorine compounds and the σ-hole effect using a polarizable multipole force fieldMechanistic Studies on Covalent Assemblies of Metal-Mediated Hemi-Aminal Ethers.In-situ generation of differential sensors that fingerprint kinases and the cellular response to their expressionIdentification and validation of novel PERK inhibitors.Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors.Application of Eukaryotic Elongation Factor-2 Kinase (eEF-2K) for Cancer Therapy: Expression, Purification, and High-Throughput Inhibitor Screening.Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.A scalable lysyl hydroxylase 2 expression system and luciferase-based enzymatic activity assay.Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.Elucidating binding modes of zuonin A enantiomers to JNK1 via in silico methods.Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1α Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target.Arrestin-3 binds c-Jun N-terminal kinase 1 (JNK1) and JNK2 and facilitates the activation of these ubiquitous JNK isoforms in cells via scaffolding.Peptide mini-scaffold facilitates JNK3 activation in cellsMELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.Signal Integration at Elongation Factor 2 Kinase: THE ROLES OF CALCIUM, CALMODULIN, AND SER-500 PHOSPHORYLATION.c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun.193 nm Ultraviolet Photodissociation Mass Spectrometry for Phosphopeptide Characterization in the Positive and Negative Ion Modes.Using docking and alchemical free energy approach to determine the binding mechanism of eEF2K inhibitors and prioritizing the compound synthesis.Construction of human activity-based phosphorylation networks.Structural Basis for the Recognition of Eukaryotic Elongation Factor 2 Kinase by CalmodulinArrestin-3-Dependent Activation of c-Jun N-Terminal Kinases (JNKs).Docking interactions of hematopoietic tyrosine phosphatase with MAP kinases ERK2 and p38α.Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine.A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib.Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth.Tinker-OpenMM: Absolute and relative alchemical free energies using AMOEBA on GPUs.Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding.Local destabilization, rigid body, and fuzzy docking facilitate the phosphorylation of the transcription factor Ets-1 by the mitogen-activated protein kinase ERK2.Novel quinoline incorporating 1,2,4-triazole/oxime hybrids: Synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations.Development of a cost effective and robust AlphaScreen® platform for application.Structural Dynamics of the Activation of Elongation Factor 2 Kinase by Ca2+-Calmodulin.Author Correction: Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding.Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanomaElucidating the Phosphate Binding Mode of Phosphate-Binding Protein: The Critical Effect of Buffer Solution.Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)Optimization of a Luminescence-Based High-Throughput Screening Assay for Detecting Apyrase ActivityA Fluorescence-Based High-Throughput Assay for the Identification of Anticancer Reagents Targeting Fructose-1,6-Bisphosphate Aldolase
P50
Q27727833-8519E279-7E6A-4FBC-8FFD-CB3DDD7C9FF3Q28243673-A5C14D7F-9210-4B32-B2A2-AF6F91EDA499Q33784701-D3DD286B-B6D0-4DDD-8BA2-F575CF8EEC32Q34708596-1D90271D-7178-4BA7-A5BC-D62BC520FDECQ34977161-F5BDFA00-BBEA-437B-9368-CC0A9F739D48Q35152423-54F742C3-5CEF-40E6-9B14-BF93C425DF77Q35210379-B207B198-3022-4D71-8A87-572DEF47279DQ35821329-95BA9DAB-E66F-4768-98CD-40D892AA90F4Q35922320-52F4180C-B1C3-4256-A726-BA9FF0FC4297Q36285050-8152401D-186B-4E6A-8952-48883FE604E0Q36326029-6FC9D5BC-4B06-4804-9325-B5CA8B13A420Q37245169-A45C8BDF-25B5-4FE6-861D-FF9C6AA5B0B3Q37371960-415BE3EA-772B-4187-9F53-185FDAD88E49Q37415694-5AA31148-9341-40D9-93CF-B59AE267BEE3Q38380188-2E5E8047-8377-4B05-B36A-CE02B9A5AF12Q38648606-FD7256B8-5E7A-450C-BB46-427C6A97AE0EQ38726534-C9A73E03-D164-4B9E-9008-48D1CF881B0CQ39110390-0FC2E9C0-DAC8-4A60-AE84-83A57A539FE8Q39593820-0A44064D-60FA-4DC4-AEFE-4776A551BB08Q40608421-83962E87-B0E1-4E2F-9BED-96DD36969630Q40836487-9F2A1569-9706-4BC0-BB57-B85654CEC94FQ41036004-A30EA00B-79EA-41DE-891C-971FD448EC41Q41833000-0250F556-6D79-43AA-82B4-931C5C87E634Q41991021-3EE2E221-CE26-4811-ADA4-9041E8370974Q42512289-C3F87E21-9CB6-44CB-A2FA-D11A7507855EQ42553470-4E96D08E-D6B9-49FD-BA8C-86B33731D7F4Q47113193-724C42EB-7241-440A-BD88-202550ECC25CQ47619144-BA1E0EFD-4689-4E81-91BC-7DC3A2398C5CQ48031360-AE644332-ED24-4C73-8EEB-D33197899F40Q48095809-CD5632F9-FB3C-4F6E-BA41-B4B080300678Q48112839-E2359E04-7201-4C06-941C-50C9912A5CA9Q50069882-8036FF7A-5AF3-44E9-8A72-B23A355FCE19Q52585212-9A69117A-8BB6-4DDB-AA0B-41D4DDFCFD47Q54978227-BEEB598B-480C-4BEE-9DC8-953731C6C5FAQ55645916-7E085CAA-7A69-4303-ADD6-272A422443E0Q58570579-047C65F5-D1BA-46DC-B8BD-87921A177D7DQ64979082-62422A57-2509-45A2-AE60-F5141F1EF8B9Q87139132-A70B7A0A-7A94-4746-B2AD-61131BA75777Q88709046-FB28F8DD-22BB-4E82-9DEF-CFE2060BF55FQ88806756-A53E0EBA-43F8-42C3-AB49-DA087D9E0EA0
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Kevin N Dalby
@en
Kevin N Dalby
@nl
type
label
Kevin N Dalby
@en
Kevin N Dalby
@nl
prefLabel
Kevin N Dalby
@en
Kevin N Dalby
@nl
P31
P496
0000-0001-9272-5129